TFC Financial Management’s AnaptysBio ANAB Stock Holding History

TFC Financial Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$68	Hold	1	–	–	﹤0.01%	966
2026 Q1	$56	Hold	1	–	–	﹤0.01%	941
2025 Q4	$49	Hold	1	–	–	﹤0.01%	928
2025 Q3	$31	Buy	+1	New	+$23	﹤0.01%	979

Other funds holding ANAB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

TFC Financial Management's ANAB Position: Q2 2026 in Review

TFC Financial Management held its AnaptysBio (ANAB) position steady in Q2 2026 at 1 share worth $68. The position accounts for ﹤0.01% of the portfolio, ranked #966.

TFC Financial Management first reported a position in ANAB in Q3 2025 and has held it in 4 quarters since. 61 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

TFC Financial Management held 1 share of AnaptysBio worth $68 as of Q2 2026.
TFC Financial Management left its AnaptysBio share count unchanged in Q2 2026.
AnaptysBio made up ﹤0.01% of TFC Financial Management's portfolio in Q2 2026, its #966 holding.
TFC Financial Management first reported a position in AnaptysBio in Q3 2025 and has held it in 4 quarters since.
61 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on TFC Financial Management's 13F filing for Q2 2026, filed 23 Jul 2026.